Predictive Oncology Price to Free Cash Flow Ratio 2010-2025 | POAI

Predictive Oncology price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as

Predictive Oncology Price to Free Cash Flow Ratio 2010-2025 | POAI

Predictive Oncology price to free cash flow ratio from 2010 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Veeva Systems (VEEV)$46.6B
Tempus AI (TEM)$13.2B
Doximity (DOCS)$12.4B
Hims & Hers Health (HIMS)$9.7B
IRhythm Technologies (IRTC)$5.3B
Hinge Health (HNGE)$4.3B
Inspire Medical Systems (INSP)$2.7B
Privia Health (PRVA)$2.6B
Heartflow (HTFL)$2.4B
Phreesia (PHR)$1.8B
Enovis (ENOV)$1.8B
10x Genomics (TXG)$1.8B
Omnicell (OMCL)$1.5B
Schrodinger (SDGR)$1.4B
Azenta (AZTA)$1.4B
Clover Health Investments (CLOV)$1.4B
Claritev (CTEV)$1.2B
Evolent Health (EVH)$1.1B
Fulgent Genetics (FLGT)$659M
Zepp Health (ZEPP)$570M
Veradigm (MDRX)$525M
Standard BioTools (LAB)$474M
Talkspace (TALK)$445M
Butterfly Network (BFLY)$390M
Carlsmed (CARL)$380M
TruBridge (TBRG)$298M
Outset Medical (OM)$244M
Health Catalyst (HCAT)$235M
SOPHiA GENETICS SA (SOPH)$233M
Nyxoah SA (NYXH)$220M